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explained by somatic mosaicism. A strongly reduced tran-
scriptional activity was observed for AR-Q738R, together 
with diminished interaction with an FxxLF motif containing 
peptide. AR-P671S also showed reduced transactivation 
ability, but no change in DNA- or FxxLF-binding capacity
and interferes with transcriptional activity for as yet unclear 
reasons.  Copyright © 2009 S. Karger AG, Basel 
 Disorders of sex development (DSD) are defined as 
any congenital condition in which the development of 
chromosomal, gonadal, or anatomical sex is atypical 
[Hughes, 2008]. One of these disorders is caused by de-
fects in androgen action. The androgen insensitivity syn-
drome (AIS) results from mutations in the X-linked an-
drogen receptor  (AR) gene. A great variety of mutations 
in the  AR gene has been reported (www.mcgill.ca//an-
drogendb), resulting in a wide spectrum of clinical phe-
notypes [Gottlieb et al., 1996].
 The androgen receptor is a transcription factor that 
belongs to the super family of nuclear receptors and is 
composed of distinct domains characteristic for steroid 
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 Abstract 
 Mutations in the androgen receptor  (AR) gene, rendering the 
AR protein partially or completely inactive, cause androgen 
insensitivity syndrome, which is a form of a 46,XY disorder of 
sex development (DSD). We present 3 novel  AR  variants 
found in a cohort of Indonesian DSD patients: p.I603N, p.
P671S, and p.Q738R. The aim of this study was to determine 
the possible pathogenic nature of these newly found unclas-
sified variants. To investigate the effect of these variants on 
AR function, we studied their impact on transcription activa-
tion, AR ligand-binding domain interaction with an FxxLF 
motif containing peptide, AR subcellular localization, and AR 
nuclear dynamics and DNA-binding. AR-I603N had com-
pletely lost its transcriptional activity due to disturbed DNA-
binding capacity and did not show the 114-kDa hyperphos-
phorylated AR protein band normally detectable after 
hormone binding. The patient with AR-I603N displays a par-
tial androgen insensitivity syndrome phenotype, which is 
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hormone receptors. The variable NH 2 -terminal domain 
(NTD) is mainly involved in transcription activation 
[Jenster et al., 1991]. The DNA-binding domain (DBD)
of the AR contains 2 zinc-clusters that specifically bind 
regulatory sequences in promoter/enhancer regions
of androgen-regulated genes [Claessens et al., 2001]. A 
short flexible hinge region, containing highly positively 
charged amino acid residues, links the DBD to the ligand-
binding domain (LBD). The AR-LBD consists of 10–12 
  -helices. Upon hormone binding, helix 12 functions as 
a lid and fixates the hormone in the ligand-binding pock-
et. As a result, a hydrophobic coactivator-binding groove 
on the LBD-surface is created [Dubbink et al., 2004]. The 
coactivator-binding groove functions as an interaction 
surface for LxxLL- and FxxLF-like motifs containing co-
activators [Dubbink et al., 2004; van de Wijngaart et al., 
2006; Trapman and Dubbink, 2007] (where L is a leucine, 
F is a phenylalanine, and x represents any amino acid) as 
well as for the FxxLF motif in the AR-NTD, important in 
the NH 2 /COOH terminal domain interaction (N/C-in-
teraction) [He et al., 2000; Steketee et al., 2002].
 Here we report 3 novel AR missense mutations found 
in a unique cohort of 101 Indonesian DSD patients. The 
aim of this study was to determine the possible patho-
genic nature of these newly found unclassified variants. 
To investigate the effect of these mutations on AR func-
tion, we studied their impact on transcription activation, 
on AR-LBD interaction with an FxxLF motif containing 
peptide, on AR subcellular localization, and on AR nu-
clear dynamics and DNA binding. Together, these data 
provide a molecular explanation for the clinical presenta-
tion of these partial androgen insensitivity syndrome 
(PAIS) patients.
 Patients, Materials, and Methods 
 Patients 
 Patient A was referred to the Dr. Kariadi Hospital, Semarang, 
Indonesia at the age of 12 years because of genital ambiguity. He 
had a male gender, and physical examination showed a bifid scro-
tum with palpable testes and perineal hypospadias, Quigley stage 
5 [Quigley et al., 1995], and breast development, Tanner stage 3–4. 
His serum concentrations of LH (2.1 IU/l) and FSH (5.3 IU/l) were 
in the normal range for early puberty, and serum testosterone 
(basal 1.6 nmol/l) rose to 20.4 nmol/l 3 days after the injection of 
1,500 IU of human chorionic gonadotropin (hCG), indicating an 
absence of disorders in testosterone biosynthesis. The serum lev-
el of anti-Müllerian hormone (AMH), which should decline un-
der the influence of testosterone in early puberty, was relatively 
high (21   g/l). He underwent surgical correction for his hypospa-
dias and breast development. Sequence analysis revealed a mo-
saic missense mutation in exon 3 of the  AR  gene (c.2170 T 1 A) at 
amino acid residue 603 (according to http://www.mcgill.ca/an-
drogendb) leading to a substitution of isoleucine with asparagine. 
Both parents were tested negative for this mutation.
 Patient B was referred to the clinic at the age of 2.5 years be-
cause of hypospadias. He had a male gender. Testes were palpable 
in a bifid scrotum, and there was scrotal hypospadias, Quigley 
stage 2. Serum LH ( ! 0.1 IU/l) and FSH (0.55 IU/l) were normal 
for his age, as was serum testosterone ( ! 0.1 nmol/l). The level of 
testosterone increased to 16.9 nmol/l after administration of 
hCG. Serum AMH was in the normal prepubertal range (68   g/l). 
Hypospadias correction was performed at the age of 3.5 years. Us-
ing sequence analysis, a missense mutation was identified in exon 
4 of the  AR gene (c.2373 C 1 T) leading to a substitution of proline 
671 with serine. Sequence analysis of the parents revealed that the 
mother was a carrier of the P671S mutation.
 Patient C was seen at the clinic at the age of 4.5 years because 
of penoscrotal hypospadias. He presented with a bifid scrotum 
and a micropenis (2 cm), Quigley stage 4. Serum LH (0.26 IU/l) 
and FSH (0.68 IU/l) were normal for his age, as was serum testos-
terone (0.1 nmol/l). The level of testosterone increased to 20.5 
nmol/l after administration of hCG. Serum AMH was in the nor-
mal prepubertal range (158   g/l). He underwent a hypospadias 
correction. Topical dihydrotestosterone (DHT) treatment with 
DHT cream during 3 months resulted in an increase of penis 
length of 1.6 cm. Using sequence analysis, a missense mutation 
was identified in exon 5 of the  AR gene (c.2575 A 1 G) leading to a 
substitution of glutamine 738 with arginine. Sequence analysis of 
the parents’ DNA revealed that the mother was a carrier of the 
Q738R mutation.
 All these patients were of Javanese Indonesian origin, had a 
46,XY karyotype and were diagnosed with PAIS.
 Mutation Analysis, Site-Directed Mutagenesis, and 
Construction of AR Expression Vectors 
 Numbering of the amino acid residues is according to the Na-
tional Center for Biotechnology Information (NCBI) accession 
number AAA51729, which refers to the AR consisting of 919 ami-
no acid residues [Lubahn et al., 1988]. Extraction of DNA from 
peripheral blood cells was performed according to standard tech-
niques. The coding exons and exon/intron boundaries of the  AR 
gene were analyzed by direct sequencing on an ABI3730XL auto-
mated sequencer. All variations except known neutral variants 
were confirmed by a 2nd sequencing experiment on DNA of the 
patients.
 The human wildtype  AR cDNA expression plasmid pSG5AR, 
a gift from Dr. Andrew Cato, was used to generate constructs en-
coding the mutant  AR s using QuickChange site-directed muta-
genesis (Stratagene, La Jolla, Calif., USA). The following sense and 
antisense primers containing the mutated sequence (depicted in 
lowercase lettering) were used: for preparation of pSG5AR-I603N 
sense primer 5  -GTGCGCCAGCAGAAATGATTGCACTAaT-
GATAAATTCC-3  and antisense primer 5  -GGAATTTATC-
AtTAGTGCAATCATTTCTGCTGGCGCAC-3  , for pSG5AR-
P671S sense primer 5  -CTATGAATGTCAGtCCATCTTTCT-
GAATGTCCTGGAAGC-3  and antisense primer 5  -GCTT-
CCAGGACATTCAGAAAGATGGaCTGACATTCATAG-3  , 
and for pSG5AR-Q738R sense primer 5  -CCAGATGGCTGT-
CATTCgGTACTCCTGGATG-3  and antisense primer 5  -CAT-
CCAGGAGTACcGAATGACAGCCATCTGG-3  . The introduc-
tion of the mutations was confirmed by sequence analysis. By 
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 digestion with restriction enzymes and subcloning, the mutant 
fragments were exchanged with wildtype fragments of vector
pSG5AR. For exchange of the I603N encoding fragment, diges-
tions with  Asp 718 and  Asp I were used. Digestions with  Asp I and 
 Bam HI were applied for the P671S and Q738R encoding frag-
ments. Green fluorescent protein (GFP)-tagged mutant AR ex-
pression constructs were generated by subcloning of the mutated 
fragments into pEGFP-AR0 [Farla et al., 2004] by  Eco RI and  Hin-
 dIII digestions. The cloning sites of all constructs were screened 
by direct sequencing. The Gal4-DBD-AR FxxLF expression con-
struct has been described previously [Dubbink et al., 2004].
 Measurements of Hormone Levels 
 Hormone levels were determined using a chemolumines-
cence-based immunometric method (Immulite 2000, Siemens-
DPC, Los Angeles, Calif., USA) for LH and FSH, a coated tube 
radioimmunoassay (Coat-a-Count, Siemens-DPC) for testoster-
one, and an enzyme immunometric assay (DPC, Webster, Tenn., 
USA) for AMH.
 Western Blot Analysis 
 For Western blot analysis COS-1 cells were seeded in 6-well 
plates (diameter 35 mm) at a density of 0.15  ! 10 6 cells per well 
in DMEM:F12 supplemented with 100 U/ml penicillin, and 100 
  g/ml streptomycin, Glutamax, 5% fetal calf serum (FCS, PerBio) 
treated with dextran coated charcoal. The next day the cells were 
transfected with either pSG5AR, pSG5AR-I603N, pSG5AR-
P671S, and pSG5AR-Q738R or empty vector pSG5, respectively. 
For each well 0.25   g DNA was mixed with 0.6   l FuGENE re-
agent (Roche Diagnostics) in MEM medium without FCS. After 
24 h 50 n M R1881 or vehicle (0.1% ethanol) was added to the wells. 
The next day the cells were washed with PBS. Per well 200   l ice-
cold SDS Laemmli sample buffer containing 10 m M dithiothreitol 
(DTT) was added and the cells were scraped with a policeman. 
The cell lysates were transferred to 1.5-ml Eppendorf tubes and 
boiled for 2 min. After a short sonication step, 7   l of the lysate 
was loaded onto a 7% SDS-polyacrylamide gel. Proteins were sep-
arated and blotted onto a nitrocellulose membrane (Schleicher & 
Schuell, Dassel, Germany). Immunoblotting was performed us-
ing polyclonal antibody SP197 [Kuiper et al., 1993], and proteins 
were visualized via the ECL method (Perkin Elmer NEL101, Shel-
ton, Conn., USA).
 Luciferase (Luc) Assays 
 For transcription activation studies Hep3B cells were cultured 
in   -MEM medium (Lonza BioWhittaker) supplemented with 5% 
FCS, 100 U/ml penicillin, and 100   g/ml streptomycin. One day 
before transfection, Hep3B cells were plated in 24-well plates at a 
density of 5  ! 10 4 cells per well. After 24 h   -MEM medium 
supplemented with 5% FCS was replaced by   -MEM medium 
with 5% charcoal-treated FCS supplemented with either vehicle 
(0.1% ethanol) or a range of 10 p M –10 n M synthetic androgen 
R1881. Four hours after addition of R1881, the cells were trans-
fected with the  AR expression constructs using FuGENE reagent. 
The DNA mixture was composed of 50 ng  AR expression con-
struct, 100 ng ARE 2 -TATA-Luc or MMTV-Luc reporter plasmid, 
and 1   l FuGENE reagent per well in 25   l   -MEM. The DNA 
mixture was pre-incubated for 2 h at room temperature before 
adding to the cells.
 For interaction assays the same procedure of cell culture was 
used as described above. All the interaction assays were per-
formed with or without addition of 1 n M R1881. A mixture of 50 
ng  AR expression construct, 50 ng Gal4-DBD-AR FxxLF expres-
sion construct, and 150 ng UAS4-TATA-Luc reporter plasmid was 
applied per well. The cells were lysed and Luc activity was mea-
sured in a Fluorescent Ascent FL (Labsystems Oy, Helsinki, Fin-
land) 24 h after DNA transfection.
 Subcellular Localization and Nuclear Mobility of GFP-Tagged 
AR Mutants 
 Two days before microscopic analysis, Hep3B cells were grown 
on glass cover slips in 6-well plates in   -MEM supplemented with 
5% FCS, 2 m M Glutamine, 100 U/ml penicillin, and 100   g/ml 
streptomycin. At least 4 h before transfection, the medium was 
substituted by medium containing 5% dextran charcoal-stripped 
FCS. Transfections were performed with 1   g GFP-AR expression 
construct in FuGENE6 transfection medium (Roche). Four hours 
after transfection, the medium was replaced by medium with 5% 
dextran charcoal-stripped FCS supplemented with 1 n M R1881 
when indicated.
 Live cell imaging and strip-FRAP analysis were performed us-
ing a confocal laser-scanning microscope (LSM510; Carl Zeiss 
MicroImaging, Inc.) equipped with a Plan-Neofluar 40 ! /1.3 NA 
oil objective (Carl Zeiss MicroImaging, Inc). Enhanced green flu-
orescent protein (EGFP) was excited using a 488 nm laser line of 
an argon laser at moderate laser power to obtain images. EGFP 
emission was detected using a 505–530 nm bandpass emission 
filter.
 Strip-FRAP analysis was performed as described by van Roy-
en et al. [2009]. Briefly, fluorescence in a narrow strip (  700
nm – corresponding to 10 pixels at zoom 6) spanning the entire 
nucleus is bleached and the recovery of fluorescence inside this 
strip is monitored in time with a 21-ms interval using a low laser 
power. Fluorescence intensity in the strip is expressed relative to 
prebleach intensities and the intensity directly after bleaching.
 Results 
 To find a possible pathogenic effect for the clinical 
phenotypes of the PAIS patients harboring  AR mutations 
p.I603N, p.P671S, and p.Q738R, the corresponding mu-
tant  AR expression constructs were generated, and the 
effects of the amino acid substitutions on AR function 
were studied in vitro .  We  investigated hyperphosphory-
lation, transcription activation, AR-LBD interaction with 
an FxxLF peptide motif, AR subcellular localization, and 
nuclear mobility and DNA-binding capacity of the dis-
tinct mutants.
 AR Isoform Pattern 
 Previous experiments have shown that in the absence 
of hormone, the AR protein displays a protein doublet of 
110–112 kDa and an extra hyperphosphorylated 114-kDa 
band upon hormone binding during SDS-polyacrylamide 
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gel electrophoresis (SDS-PAGE). Part of the hormone-in-
duced phosphorylation occurs following DNA binding 
and during or following transcription regulation [Jenster 
et al., 1994]. To study the effect of the PAIS-associated  AR 
mutations on phosphorylation, wildtype  AR and AR mu-
tants I603N, P671S, and Q738 were expressed in COS-1 
cells by transient transfection of the distinct  AR con-
structs and Western blot analysis was performed after 
SDS-PAGE.  Figure 1 shows expression of the 110–112-
kDa protein doublet by wildtype AR and all mutant ARs. 
However, incubation with the synthetic androgen R1881 
induced expression of the hyperphosphorylated 114-kDa 
protein band in case of wildtype AR, AR mutants P671S 
and Q738R, but not of the AR mutant I603N ( fig. 1 , lane 
5).
 Transcription Activation 
 Next, we studied transcriptional activation by the dif-
ferent mutant ARs. Hep3B cells were transiently trans-
fected with one of the  AR expression constructs described 
above and an ARE 2 -TATA-Luc reporter construct. Cells 
were incubated in the presence of increasing concentra-
tions of R1881. The AR-I603N mutant completely lost its 
transactivation potential even at the highest hormone 
concentration tested ( fig. 2 ). Both the Q738R and P671S 
mutants showed reduced maximal transactivation capac-
ity of 56 and 78% of wildtype AR activity, respectively, in 
the presence of 10 –8  M R1881. In addition, higher R1881 
concentrations were required for androgen induction,
as at 10 –10  M R1881 their activities were only 10 and 32% 
of wildtype AR, respectively. In CHO cells and with a 
MMTV-Luc reporter construct, similarly reduced tran-
scriptional activities were observed for the distinct mu-
tants (data not shown).
 Intracellular Distribution in Living Cells 
 To study the distribution of AR in living cells, wild-
type AR, a non-DNA-binding AR mutant (AR-A573D) as 
a positive control, and the 3 AR mutants were N-termi-
nally tagged with GFP. In the absence of hormone, the 
proteins were mainly cytoplasmic (left panels in  fig. 3 a–
c, e, g). After addition of 1 n M R1881, the GFP-AR trans-
located to the nucleus (right panels in  fig. 3 a–c, e, g). In 
the nucleus AR-P671S and AR-Q738R displayed a typical 
punctate distribution pattern similar to wildtype AR 
(right panels in  fig. 3 a, e, g) [Farla et al., 2004; van Royen 
et al., 2007]. Nuclei of cells transfected with AR-I603N, 
however, lacked this punctate pattern and showed a more 
homogeneous distribution (right panel in  fig. 3 c), similar 
to the non-DNA-binding mutant AR-A573D (right panel 
in  fig. 3 b) [Farla et al., 2004].
 FRAP was used to study the intranuclear mobility of 
the AR mutants. In concordance with their distribution 
pattern, AR-P671S and AR-Q738R showed a transient 
immobilization similar to wildtype AR ( fig. 3 f, h), where-
as the redistribution of AR-I603N was as fast as the non-
DNA-binding mutant AR-A573D ( fig. 3 d).
 Interaction with an   -Helical FxxLF Peptide Motif 
 Upon hormone binding, a hydrophobic groove is 
formed in the AR-LBD surface. This coactivator-binding 
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 Fig. 1. Western blot analysis of PAIS-associated AR mutants. 
Wildtype AR (wt) and AR mutants I603N, P671S, and Q738R 
were expressed in COS-1 cells in the absence (–) or presence (+) of 
50 n M R1881. After SDS-PAGE and immunoblotting, the AR pro-
tein was visualized by polyclonal antibody Sp197. ev = Empty vec-
tor.  
 Fig. 2. Transcription activation assay in Hep3B cells. Dose-re-
sponse curves of wildtype AR, AR-P671S, AR-Q738R, and AR-
I603N in the presence of increasing amounts of R1881. The activ-
ity of wildtype AR at 10 n M R1881 was set at 100% and the other 
data points were calculated relative to that. Values represent the 
means  8 SEM of 2 independent experiments, performed in trip-
licate. 
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 Fig. 3. High-resolution confocal images 
and strip-FRAP analysis of cells express-
ing GFP-tagged AR mutants. Confocal 
images of Hep3B cells expressing GFP-
tagged wildtype AR ( a ) and mutant GFP 
constructs ( b ,  c ,  e ,  g ) in the absence (left 
panels) and presence (right panels) of 1 n M 
R1881. The nuclei in the hormone-treated 
cells were represented at 1.6 ! higher mag-
nification as compared to the cells in the 
‘minus hormone’ situation in order to em-
phasize the differences in the speckled 
patterns in the nuclei. Bars represent 5 
  m.  d ,  f ,  h Strip-FRAP analysis of the in-
dicated AR mutants in the presence of 1 
n M R1881 (red curves). Redistribution of 
wildtype AR (grey curve) and a non-DNA-
binding mutant (AR-A573D) (black curve) 
were plotted as references. DCC = Dex-
tran-coated charcoal. 
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 Fig. 4. Structure of the androgen receptor 
ligand-binding domain (LBD).  a Ribbon 
representation. The ligand, positioned in 
the ligand-binding pocket, is indicated in 
red. Helices 3, 4, and 5 are shown in dark 
blue, helix 12 is purple. An FxxLF peptide 
motif interacting with the cofactor-bind-
ing groove in the LBD surface is displayed 
in brown. The region in the red square is 
enlarged and rotated in  b .  b Position of an 
FxxLF peptide (brown) in the cofactor-
binding groove of the LBD. Important 
amino acid residues are indicated in the 
LBD, lining the cofactor-binding groove, 
in which missense mutations have a prov-
en correlation with AIS. Colors are as 
shown in  a . The figures are generated in 
ViewerLite 5.0 (Accelrys) using the coor-
dinates of Protein Data Bank entry 
1XOW. 
 Elfferich et al. Sex Dev 2009;3:237–244242
groove is lined by 13 amino acid residues, which reside in 
helices H3, H4, H5, and H12 ( fig. 4 ), one of which is Q738 
[Trapman and Dubbink, 2007]. The coactivator groove 
interacts with LxxLL- and FxxLF-like motifs present in 
AR cofactors and with the FxxLF motif in the AR-NTD. 
To investigate the effect of the  AR  mutations on LxxLL 
and FxxLF motif interaction, binding to the AR FxxLF 
motif was studied. For this purpose, Hep3B cells were 
transiently transfected with constructs expressing a
Gal4-DBD-FxxLF fusion protein and full-length ARs to-
gether with an UAS4-TATA-Luc reporter construct. Ex-
periments were done in the absence and presence of 1 n M 
R1881. Interaction of the AR FxxLF motif with AR-I603N 
and AR-P671S was strongly induced by the hormone to 
similar levels as shown for wildtype AR ( fig. 5 ). However, 
AR FxxLF interaction with AR-Q738R was 5-fold de-
creased compared to wildtype AR. These data indicate 
that cofactor binding to the coactivator groove is hin-
dered by Q738R substitution, but not by I603N and P671S 
substitutions.
 Discussion 
 In this study we report 3 novel mutations in the AR 
gene, p.I603N, p.P671S, and p.Q738R, found in a cohort 
of 101 Indonesian DSD patients. All 3 patients presented 
with a PAIS phenotype. We performed extensive func-
tional analyses of the mutant ARs to understand how 
these missense mutations correlate with the clinical phe-
notype of the patients. The results of our experiments are 
summarized in  table 1 .
 The AR-I603N mutation is located in the DBD region 
of the AR, close to the D box in the 2nd zinc cluster. The 
D box is involved in AR dimerization and hormone-re-
sponsive element (HRE) half-site recognition. Amino 
acid substitutions in the D box normally result in a PAIS 
phenotype [Giwercman et al., 2004]. Our results show 
that the AR-I603N mutation leads to a defective hor-
mone-induced hyperphosphorylation of the protein and 
absence of the 114-kDa phosphoprotein band probably 
due to a disturbed DNA binding. AR-I603N displays a 
normal translocation to the nucleus upon hormone stim-
ulation but has completely lost its DNA-binding capacity 
as shown by live cell imaging, which explains its total lack 
of transcriptional activity from 2 distinct promoters. Pre-
viously, we have shown that disrupted DNA binding
underlies a complete androgen insensitivity syndrome 
(CAIS) phenotype of a patient harboring an A573D mu-
tation in the 1st zinc cluster [Brüggenwirth et al., 1998; 
Farla et al., 2005]. However, despite the presence of an in-
activating AR-I603N mutation, the patient presented 
with a PAIS phenotype and partly suppressed AMH lev-
els. Examination of the DNA sequence of exon 3 showed, 
besides the mutant, also a wildtype nucleotide at position 
2170 in DNA from blood cells of the patient ( fig. 6 ), in-
dicative for somatic mosaicism. A similar occurrence of 
somatic mosaicism has previously been reported in a 
PAIS patient harboring a wildtype  AR and an  AR with a 
premature stop codon in the NTD [Holterhus et al., 1997]. 
Variable tissue distribution of wildtype and mutant  AR 
alleles may also underlie the PAIS phenotype of the AR-
I603N patient.
Table 1. Summary of functional studies of androgen receptor mu-
tants leading to partial androgen insensitivity syndrome
Mutant Hyperphosphor-
ylation (114-kDa
isoform) 
Trans-
activa-
tion
Coacti-
vator
binding
Transient 
immobili-
zation
I603N absent 4 = 4
P671S present 8 = =
Q738R present 8 4 =
4 = diminished, no activity; = = wildtype activity; 8 = 50–
75% wildtype activity.
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 Fig. 5. Interaction assay as measured in Hep3B cells transfected 
with wildtype AR and AR mutant constructs. The AR FxxLF-mo-
tif peptide construct and the UAS4-TATA-Luc reporter plasmid 
were used in this interaction assay. Interaction was measured in 
the absence (open bars) and presence of 1 n M R1881 (black bars). 
On top of the bars, standard deviation is displayed plus the fold 
induction. DCC = Dextran-coated charcoal. 
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 The AR-P671S mutation is located in helix 1 of the 
LBD and encoded by exon 4 of the  AR gene. This proline 
is highly conserved among human steroid receptors, un-
derscoring an important role for this amino acid. AR-
P671S substitution results in a reduced transcription ac-
tivity to 78% at physiological hormone concentrations, 
which could be partly overcome by increasing the level of 
androgen. The reason for this decreased activity is not yet 
understood, because in all other functional assays the 
AR-P671S mutation behaved like wildtype AR. Hiort and 
colleagues [1996] reported a different mutation of the 
same amino acid residue, P671H, in a PAIS patient, al-
though its effect on AR function has not been tested. Our 
data indicate that suboptimal AR functioning due to the 
P671S mutation may be the underlying cause of the PAIS 
phenotype in this patient.
 AR-Q738 is located in the hydrophobic coactivator 
groove in the surface of the AR-LBD ( fig. 4 ) [Dubbink et 
al., 2004; He et al., 2004; Hur et al., 2004]. The coactivator 
groove is essential for both cofactor binding via LxxLL-
and FxxLF-like motifs and interaction with the FxxLF 
motif in the NTD. We have shown that AR-Q738R sub-
stitution does not affect the AR isoform pattern, intra-
nuclear distribution and mobility, and DNA binding, but 
results in a 2-fold decreased transcriptional activity at 
high hormone concentrations. The effect on transcrip-
tion is even more pronounced at lower, more physiologi-
cal hormone levels, yielding only 10% of wildtype activ-
ity. Most likely, the underlying reason for loss of activity 
is the strongly diminished interaction with the AR FxxLF 
motif. Our data are in line with previous results showing 
that abrogation of N/C interaction via the coactivator 
groove reduced transcriptional activity [He et al., 2000; 
Dubbink et al., 2004]. According to crystal structures, 
residue Q738 makes hydrophobic contacts with the N-
terminal F (F+1) of the AR FxxLF motif ( fig. 4 b) [He et 
al., 2004; Hur et al., 2004]. Substitution of the polar but 
uncharged glutamine residue by a charged arginine resi-
due is probably not allowed because of interference with 
hydrophobic interactions with F+1, thus destabilizing the 
FxxLF motif interaction. It is likely that binding of AR 
cofactors that largely depends on AR interaction via the 
coactivator groove in the LBD is also negatively influ-
enced by the Q738R mutation [Dubbink et al., 2004, 2006; 
van de Wijngaart et al., 2006]. Altogether, these data un-
derscore the essential physiological role of AR-Q738 in 
FxxLF motif binding, including binding to the NTD, i.e., 
N/C interaction.
 Several other amino acid substitutions in residues lo-
cated in the hydrophobic coactivator groove are PAIS-
associated. The F725L and I737T mutations disrupt the 
N/C terminal interaction [Quigley et al., 2004]. The 
L712F was found several times in PAIS patients, and the 
Q733H mutation displayed a mosaic pattern [Hiort et al., 
1998].
Control
Patient A
R
R
F
F
 Fig. 6. Sequencing analysis pattern of a part of exon 3 of the  AR 
gene in control DNA and DNA of patient A (Sequencing analysis 
version 5.3.1). The arrow indicates base pair position 2170 of the 
 AR gene. F = Forward strand; R = reverse strand. In the basecall-
ing panel W represents an A or T nucleic acid. In DNA from pa-
tient A a mosaic pattern is seen at position 2170. 
 Elfferich et al. Sex Dev 2009;3:237–244244
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 In conclusion, we describe 3 novel PAIS-associated  AR 
mutations present in the DBD (I603N), helix 1 of the LBD 
(P671S), and coactivator groove (Q738R) and provide in-
sights in the clinical phenotypes of the patients harboring 
these mutations. AR-I603N entirely lost its DNA-binding 
capacity and transcriptional activity. Probably because of 
a somatic mosaicism, the patient displays a PAIS pheno-
type. The AR-P671S mutation interfered with transcrip-
tional activity for as yet unclear reasons, and AR-Q738R 
replacement strongly reduced transcriptional activity be-
cause of abrogated capability to perform N/C interaction 
and cofactor binding. Altogether, our functional analysis 
of these mutants further increases the molecular under-
standing of AR functioning.
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